Mesiglic

Metformin Hydrochloride / Sitagliptin, the active ingredient in Mesiglic, is a Biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Mesiglic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesiglic is used to improve glycaemic control in patients with type 2 diabetes mellitus, acting on multiple pathways of glucose regulation. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Adjunct to diet and exercise: enhances the effectiveness of lifestyle interventions. - Combination therapy with other antidiabetics: provides additional glucose‑lowering benefit when used with insulin or other oral agents.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Mild hypoglycaemia: especially when combined with insulin or sulfonylureas. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction observed in some patients.

Serious or Rare Side Effects: - Lactic acidosis: potentially fatal metabolic disturbance. - Severe hypoglycaemia: marked low blood glucose requiring medical intervention. - Pancreatitis: inflammation of the pancreas. - Hepatic dysfunction: elevated liver enzymes or liver injury. - Allergic reactions: rash, pruritus, or angio‑edema. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, evaluate patient-specific factors and monitor for adverse events. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Hepatic impairment: use with caution; monitor liver enzymes. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia or tissue hypoperfusion. - Pregnancy and lactation: safety not established; discuss risks with a healthcare professional. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mesiglic may interact with several medicines; clinical judgment is required. Major Interactions (Avoid): - Iodinated contrast media: increased risk of renal dysfunction and lactic acidosis. - Alcohol: potentiates metformin‑related lactic acidosis. - Cimetidine: may raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: can mask symptoms of hypoglycaemia. - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes during combined use.